(AWP) Relief partner NeuroRx has achieved the set goals in its phase IIb / III study with Zyesami (aviptadil acetate). As the US company announced on Monday, the drug was administered intravenously to seriously ill patients who were infected with Covid-19.
Thus, across all patients and locations, Zyesami achieved the goal of successful recovery from respiratory insufficiency on days 28 and 60 and also showed a significant advantage in survival after the ventilation status control.
Recovery from respiratory arrest (without relapse) with discharge from acute care and survival during the observation period was the goal set by the US FDA for the study.
– .
